Guangzhou Virotech Pharmaceutical Co., Ltd.

This early-phase study tests a modified virus called VRT106 that is injected directly into tumors to see if it is safe and can shrink cancers. About 30 adults with advanced solid tumors that have not responded to standard treatments will receive the virus. The main goal is to fin…

This study tests whether adding an experimental drug called VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG). About 10 adults aged 18 to 75 will receive the combination treatment. The main goal i…

This study tests a new drug, VRT106, in 42 adults whose glioblastoma (a serious brain cancer) has come back or worsened. The main goal is to see if the drug is safe and find the best dose. Researchers will also check if it helps shrink tumors or extend life, but this is not a cur…

This study tests a new drug combination (VRT106, camrelizumab, and apatinib) in about 66 adults with advanced liver cancer whose previous immunotherapy stopped working. The goal is to see if the combination can shrink tumors or slow disease progression. Participants will receive …